According to multiple clinical studies on PARP inhibitor maintenance treatment for platinum-sensitive recurrent ovarian cancer patients, the median duration of progression-free survival of patients either with or without homologous recombination deficiency in PARP inhibitor group ranged from 7.4 to 13.6 months. This evidence concerns the gene PARP1 and ovarian carcinoma.